NCT02684383View on ClinicalTrials.gov

Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

Not specified

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Dengue
Interventions
BIOLOGICAL

rDEN3∆30

10\^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm

BIOLOGICAL

Placebo

Administered by subcutaneous injection in the deltoid region of the upper arm

Trial Locations (2)

21205

Center for Immunization Research (CIR), Johns Hopkins School of Public Health, Baltimore

05401

University of Vermont Medical Center, Burlington

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02684383 - Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine | Biotech Hunter | Biotech Hunter